Search results
Showing 106 to 120 of 269 results for patient decision aid
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.
View recommendations for IPG656Show all sections
Emergency and acute medical care in over 16s: service delivery and organisation (NG94)
This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)
In development Reference number: GID-HTE10070 Expected publication date: TBC
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.
Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)
Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture.
View recommendations for IPG623Show all sections
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
important to patients? Any explanatory notes(if applicable) There is a lack of information on the long-term impact of cholecystectomy on...
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.